PLUS THERAPEUTICS Inc.
PSTV evidence brief
What we can confirm
- BioSniper Score:
- 4.3 / 10
- Market Cap:
- $26.6M
- Lead Asset:
- 188rnl-bam (Preclinical)
What it means
What to watch
Prepared research question
What matters most for PSTV—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PSTV
PLUS THERAPEUTICS Inc. (PSTV) is a U.S. healthcare company developing precision diagnostics and targeted radiopharmaceuticals for central nervous system (CNS) cancers, with a lead radiotherapeutic candidate and a commercialized cerebrospinal fluid assay platform.
Key risk: Low cash runway
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$26.6M
Cash Runway
—
Lead Asset
188rnl-bam (Preclinical)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for PLUS THERAPEUTICS Inc..
PLUS THERAPEUTICS Inc. (PSTV) is a U.S. healthcare company developing precision diagnostics and targeted radiopharmaceuticals for central nervous system (CNS) cancers, with a lead radiotherapeutic candidate and a commercialized cerebrospinal fluid assay platform.
- Cash & equivalents of $2.4M as of 2026-06-30 [sec].
- Total revenue of $0.4M and net income of -$9.0M as of 2026-06-30 [sec].
- Shareholders' equity of $5.5M as of 2026-06-30 [sec].
- Lead radiotherapeutic candidate is rhenium (186Re) obisbemeda, being studied in Phase 1/2 trials for leptomeningeal metastases and glioblastoma [sec_mda · as of 2026-08-14].
- Wholly owned subsidiary CNSide Diagnostics commercializes the CNSide® CSF assay, which received CLIA accreditation and has national payer agreements with United Healthcare, Humana, Highmark, and Blue Shield of California [sec_mda · as of 2026-05-15].
What works
- The CNSide Test has received CLIA accreditation and signed national agreements with four major payers, expanding patient access [sec_mda · as of 2026-05-15].
- The company has secured a $3.0 million DoD Award to support expansion of its pediatric brain cancer clinical trial [sec_mda · as of 2026-08-14].
- The lead radiotherapeutic candidate is being advanced through multiple clinical trials, including a Phase 2 glioblastoma trial (ReSPECT-GBM) with an end-of-phase meeting with FDA targeted for Q4 2026 [sec · filed 2026-03-31].
What to weigh
- The company reported a net loss of $9.0M on only $0.4M revenue as of 2026-06-30, indicating significant cash burn relative to revenue [sec].
- Cash and equivalents of $2.4M as of 2026-06-30 is low relative to planned clinical trial and manufacturing scale-up activities [sec].
- The company acknowledges that its inability to raise additional cash would have a material adverse impact on operations and Nasdaq listing compliance [sec_mda · as of 2026-08-14].
- The company's radiotherapeutic candidates are still in early-to-mid-stage clinical trials, with no approved products generating revenue yet [sec_mda · as of 2026-08-14].
From the filings
Quoted directly from source documents.
CNSide Test CLIA accreditation and payer agreements
“The laboratory for the CNSide Test in Houston, Texas has received a certificate of accreditation from the Centers for Medicare & Medicaid Services (CMS) which deems the lab compliant with Clinical Laboratory Improvement Amendments ("CLIA") regulations. Furthermore, CNSide Diagnostics has signed national agreements to provide the CNSide Test with four payers, including United Healthcare, Humana, Highmark, and Blue Shield of California”
SEC MD&A · May 15, 2026
DoD Award for pediatric brain cancer trial
“Effective September 1, 2024, we entered into an agreement with the Department of Defense office of the Congressionally Directed Medical Research Programs to receive a $3.0 million fund for research and development purposes ("DoD Award") over a three-year period.”
SEC MD&A · August 14, 2026
Catalyst timeline
- 2025-07-02 · Phase 1 start for leptomeningeal metastases trial — A multicenter Phase 1 study of rhenium (186Re) obisbemeda administered via intraventricular catheter for any primary solid tumor cancer with leptomeningeal metastases.
- 2025-09-01 · Phase 1/2a start for pediatric brain cancer trial — A two-part trial to determine maximum tolerated dose, safety, and tolerability of rhenium (186Re) obisbemeda delivered via convection enhanced delivery in pediatric ependymoma and high-grade glioma.
Risks & what to watch (4)›
Key risks
- Low cash runway — Cash of $2.4M as of 2026-06-30 may be insufficient to fund planned clinical and manufacturing activities without additional capital [sec].
- Dependence on future fundraising — Company states inability to raise cash would materially harm operations and Nasdaq listing compliance [sec_mda · as of 2026-08-14].
- No approved revenue-generating products — Lead candidates are in Phase 1/2 trials; CNSide Test is commercialized but revenue is minimal ($0.4M total) [sec].
- Clinical trial execution risk — Multiple trials (LM, GBM, pediatric) are ongoing with enrollment and data milestones in 2026; delays could impact cash needs [sec · filed 2026-03-31].
What to watch
- Data from the ReSPECT-LM Phase 1/2 optimal dose/interval trial expected in Q3 2026 [sec · filed 2026-03-31].
- Completion of enrollment and end-of-phase meeting with FDA for ReSPECT-GBM Phase 2 trial targeted by Q4 2026 [sec · filed 2026-03-31].
- First patient enrollment in the ReSPECT-PBC Phase 1 pediatric brain cancer trial anticipated in 2026 [sec_mda · as of 2026-08-14].
- Shift of REYOBIQ radiotherapeutic manufacturing to SpectronRx for commercial scale, targeted to be pivotal-trial-ready in early 2027 [sec · filed 2026-03-31].
Sources: Catalysts · SEC filings · SEC MD&A · Generated October 13, 2026 · How we verify sources →
Run PLUS THERAPEUTICS Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available PLUS THERAPEUTICS Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 1.57 · 0% dilution
Lead: Preclinical
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Short Interest
as of May 12, 2026- % of float
- 18.0%
- Days to cover
- 2.1
- Shares short
- 1,232,913
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PSTV short interestGovernance
Frequently asked questions
What is the AI investment thesis for PLUS THERAPEUTICS Inc.?
PLUS THERAPEUTICS Inc. (PSTV) is a U.S. healthcare company developing precision diagnostics and targeted radiopharmaceuticals for central nervous system (CNS) cancers, with a lead radiotherapeutic candidate and a commercialized cerebrospinal fluid assay platform.
What is PLUS THERAPEUTICS Inc.'s lead drug candidate?
PLUS THERAPEUTICS Inc.'s most advanced tracked candidate is 188rnl-bam (Preclinical) for Solid organ cancers including primary and secondary liver cancers.
Who is the CEO of PLUS THERAPEUTICS Inc.?
Dr. Marc H. Hedrick M.B.A., M.D. is the chief executive officer of PLUS THERAPEUTICS Inc. (PSTV).
Where is PLUS THERAPEUTICS Inc. headquartered?
PLUS THERAPEUTICS Inc. (PSTV) is headquartered in Houston, TX, United States.
What therapeutic areas does PLUS THERAPEUTICS Inc. focus on?
PLUS THERAPEUTICS Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.